News stories about Hemispherx BioPharma (NYSE:HEB) have trended somewhat positive on Tuesday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hemispherx BioPharma earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 47.0384760692786 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

Hemispherx BioPharma (HEB) opened at 0.44 on Tuesday. Hemispherx BioPharma has a 12-month low of $0.30 and a 12-month high of $2.64. The stock’s market capitalization is $11.64 million. The stock has a 50 day moving average price of $0.46 and a 200-day moving average price of $0.53.

ILLEGAL ACTIVITY WARNING: “Hemispherx BioPharma (NYSE:HEB) Getting Somewhat Favorable News Coverage, Study Shows” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/15/hemispherx-biopharma-nyseheb-getting-somewhat-favorable-news-coverage-study-shows.html.

Hemispherx BioPharma Company Profile

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

Insider Buying and Selling by Quarter for Hemispherx BioPharma (NYSE:HEB)

Receive News & Stock Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related stocks with our FREE daily email newsletter.